Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Hose

Showing results (181-190 of 189) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 189 results.
Blood|May 19, 2017
Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myelomaMichelle M McDonald, Michaela R Reagan, Scott E Youlten, et al.
Nature Genetics|March 19, 2013
The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myelomaNiels Weinhold, David C Johnson, Daniel Chubb, et al.
The Lancet. Haematology|February 1, 2024
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trialElias K Mai, Hartmut Goldschmid, Kaya Miah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2012
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trialPieter Sonneveld, Ingo G H Schmidt-Wolf, Bronno van der Holt, et al.
Haematologica|February 13, 2008
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disordersAndy C Rawstron, Alberto Orfao, Meral Beksac, et al.
Nature Genetics|August 20, 2013
Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma riskDaniel Chubb, Niels Weinhold, Peter Broderick, et al.
Leukemia|June 3, 2024
CD8<sup>+</sup> CD28<sup>-</sup> regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III studyKatharina Kriegsmann, Gigi Nu Hoang Quy Ton, Mohamed H S Awwad, et al.
Leukemia|February 16, 2020
Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive diseaseMike J Mason, Carolina Schinke, Christine L P Eng, et al.
Blood|April 27, 2019
A niche-dependent myeloid transcriptome signature defines dormant myeloma cellsWeng Hua Khoo, Guy Ledergor, Assaf Weiner, et al.
Pageof 19

Showing results (181-190 of 189) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 189 results.
Blood|May 19, 2017
Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myelomaMichelle M McDonald, Michaela R Reagan, Scott E Youlten, et al.
Nature Genetics|March 19, 2013
The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myelomaNiels Weinhold, David C Johnson, Daniel Chubb, et al.
The Lancet. Haematology|February 1, 2024
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trialElias K Mai, Hartmut Goldschmid, Kaya Miah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2012
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trialPieter Sonneveld, Ingo G H Schmidt-Wolf, Bronno van der Holt, et al.
Haematologica|February 13, 2008
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disordersAndy C Rawstron, Alberto Orfao, Meral Beksac, et al.
Nature Genetics|August 20, 2013
Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma riskDaniel Chubb, Niels Weinhold, Peter Broderick, et al.
Leukemia|June 3, 2024
CD8<sup>+</sup> CD28<sup>-</sup> regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III studyKatharina Kriegsmann, Gigi Nu Hoang Quy Ton, Mohamed H S Awwad, et al.
Leukemia|February 16, 2020
Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive diseaseMike J Mason, Carolina Schinke, Christine L P Eng, et al.
Blood|April 27, 2019
A niche-dependent myeloid transcriptome signature defines dormant myeloma cellsWeng Hua Khoo, Guy Ledergor, Assaf Weiner, et al.
Pageof 19